Early diagnosis and prevention of AML

preleukemic stem cells give rise to AML and other blood malignancies and can be identified years before diagnosis. Recently, we were able to predict AML years before diagnosis by analyzing molecular signatures among healthy individuals. In this study specific mutations found among healthy individual predicted AML. Some of these mutations, specifically, in the spliceosome machinery can be targeted and we are now working on designing the clinical trials for AML prevention. The access to the electronic health records of 3.2 million Israelis allowed us to develop algorithms for AML prediction based on routine clinical information and this will allow us to access healthy individuals offer the genetic testing and identify individuals with high risk to develop AML